OncoSil Medical LtdASX: OSL

120 German Hospitals entitled to negotiate fee for OncoSil

· Issued by OncoSil Medical Ltd

Filed with ASX · · 2 pages · English

Summary by 6ix AI

This marks a significant increase in hospital participation compared to the previous year, reflecting growing demand and recognition of the device in Germany. The approval follows earlier classifications and directives from German health authorities regarding the treatment method for pancreatic cancer. CEO Nigel Lange expressed optimism about the progress and acceptance of the OncoSil device among healthcare professionals in Germany.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

OncoSil Medical Ltd on 6ix

Story so far

Earlier from OncoSil Medical

Later from OncoSil Medical

All OncoSil Medical news releases